Core Points - The company has approved a cash dividend distribution plan for the first half of 2025, proposing a cash dividend of 2.00 RMB per 10 shares, totaling approximately 200.50 million RMB based on the current total share capital [2][27][29] - The company has received medical device registration certificates for its continuous glucose monitoring systems, enhancing its product offerings in diabetes care [4][6] - The company has invested approximately 27.21 million USD in Inogen, acquiring 9.9% of its shares and establishing a strategic cooperation agreement [7] - The company has obtained EU MDR certification for its automated external defibrillator (AED) products, which will enhance its competitiveness in the emergency medical equipment market [9][10] - The company has extended the duration of its employee stock ownership plan by 24 months, now set to expire in August 2027 [30][31] Financial Data - The company's net profit for the first half of 2025 was approximately 876.29 million RMB, with a distributable profit of about 8.51 billion RMB as of June 30, 2025 [27][29] - The total number of shares for the cash dividend distribution is based on the company's existing total share capital of 1,002,476,929 shares [27][29] Corporate Governance - The company held its sixth board meeting on August 22, 2025, where the half-year report and profit distribution plan were approved [14][26] - The supervisory board also approved the half-year report and profit distribution plan, confirming compliance with legal and regulatory requirements [21][23]

Core Viewpoint - The company plans to repurchase shares through a centralized bidding process, with a total amount ranging from RMB 30 million to 60 million, aimed at employee stock ownership plans or equity incentives [1][2][4]. Summary by Sections Repurchase Plan Overview - The repurchase amount is set between RMB 30 million and 60 million [1][2]. - The funding source for the repurchase will be the company's own funds [1][5]. - The maximum repurchase price is capped at RMB 25 per share, which is 150% of the average trading price over the last 30 trading days prior to the board's decision [1][4]. - The repurchase will be conducted via centralized bidding [1][3]. - The duration for the repurchase is 12 months from the board's approval [1][3]. Purpose and Use of Repurchased Shares - The repurchased shares will be used for employee stock ownership plans or equity incentives [1][3][4]. - If the shares are not fully utilized for these purposes within three years, the company will follow the necessary procedures to cancel the unused shares and reduce registered capital accordingly [4][5]. Implementation and Conditions - The repurchase plan requires approval from at least two-thirds of the board members and does not need to be submitted to the shareholders' meeting [2][3]. - The estimated number of shares to be repurchased is between 120,000 and 240,000, representing 0.17% to 0.34% of the total share capital [2][4]. - The company will adjust the repurchase price if there are any capital changes, such as stock splits or dividends [4][5]. Financial Impact - The total amount for the repurchase represents approximately 1.10% of the company's total assets and 1.26% of the equity attributable to the parent company [5]. - The company asserts that the repurchase will not significantly impact its daily operations, financial status, research and development, profitability, or debt servicing capabilities [5][6]. Management and Compliance - The board has authorized the management to handle all matters related to the repurchase, including adjustments based on market conditions [7]. - There are no current plans for share reduction by directors, senior management, or major shareholders in the next three to six months [6][8].

Core Viewpoint - Shenzhen BGI Genomics Co., Ltd. has revised its 2024 Restricted Stock Incentive Plan and Employee Stock Ownership Plan to better execute its current strategic plan and enhance market competitiveness [1][2]. Group 1: Restricted Stock Incentive Plan - The company has made revisions to the 2024 Restricted Stock Incentive Plan to effectively motivate the core team to increase the market share of sequencing instruments among non-related customers [1][2]. - The revisions comply with relevant regulations and do not harm the interests of the company and all shareholders [1][2]. Group 2: Employee Stock Ownership Plan - The company has also revised the 2024 Employee Stock Ownership Plan to align with its strategic goals and improve market coverage [2]. - The changes made to the Employee Stock Ownership Plan are consistent with applicable guidelines and do not negatively impact the interests of the company and its shareholders [2].

Meeting Overview - The fifth meeting of the board of directors was held on August 12, 2025, with all seven directors present, meeting the legal quorum requirements [1] - The meeting was chaired by Chairman Sun Zhen, and the procedures complied with the Company Law and the company's articles of association [1] Resolutions Passed - A resolution was passed regarding a sales employee suspected of embezzlement through forgery of company documents, leading to a report to the Beijing Public Security Bureau [1] - The company will correct accounting errors from Q4 2023 to Q1 2025 using retrospective restatement, affecting multiple financial reports including the 2023 annual report and 2024 quarterly reports [1] Employee Stock Ownership Plan - The board decided to revoke the shares and benefits of an employee in the stock ownership plan due to legal violations, impacting the performance assessment of their department [2] - The resolution regarding the 2025 semi-annual report was approved, confirming that it accurately reflects the company's operational status without any misleading statements [2] Fund Management - The board reviewed the management of raised funds for the first half of 2025, ensuring compliance with relevant regulations and preparing a special report on fund usage [3] - A resolution was passed to establish a dedicated fund account for a subsidiary, aimed at improving fund utilization efficiency and aligning with the company's long-term development needs [3]

Core Viewpoint - Shenzhen BGI Intelligent Manufacturing Technology Co., Ltd. has proposed a 2024 employee stock ownership plan aimed at aligning the interests of employees and shareholders, enhancing corporate governance, and promoting long-term sustainable development [3][10][21]. Summary by Sections 1. Purpose and Principles of the Plan - The employee stock ownership plan is designed to establish a profit-sharing mechanism between employees and shareholders, improve corporate governance, and enhance employee motivation and creativity [10][11]. - Participation in the plan is voluntary, and the company will not impose mandatory participation on employees [11][12]. 2. Participants and Eligibility - The plan will include a maximum of 35 employees, consisting of directors (excluding independent directors), supervisors, senior management, and core business personnel [4][12]. - The selection of participants will be based on their contributions to the company's core business and strategic direction [15]. 3. Funding and Stock Source - The total funding for the plan will not exceed RMB 37.7868 million, with each unit priced at RMB 1.00 [4][13]. - The shares will be sourced from the company's repurchased A-shares, with a maximum holding of 1.445 million shares, accounting for 0.35% of the total share capital [5][18]. 4. Pricing and Valuation - The share purchase price is set at RMB 26.15 per share, which is based on the average trading price prior to the announcement of the plan [15][16]. - The pricing strategy aims to ensure fairness and reasonableness, reflecting the company's operational status and industry conditions [16]. 5. Lock-up and Vesting Period - The plan has a duration of 48 months, with shares vesting in two phases: 50% after 12 months and the remaining 50% after 24 months [6][20]. - The vesting of shares is contingent upon the company's performance and individual assessments of the participants [20][21]. 6. Management and Governance - The plan will be managed by a dedicated management committee, which will oversee daily operations and represent the interests of the participants [24][25]. - The management committee is responsible for ensuring compliance with legal and regulatory requirements and safeguarding the rights of the participants [25][29]. 7. Performance Assessment - The performance assessment will be based on company-wide revenue growth and individual performance metrics, with specific targets set for the years 2024 and 2025 [21][22]. - The assessment results will determine the unlock ratios for the shares, aligning employee incentives with company performance [22][23].

Core Viewpoint - Shenzhen BGI Genomics Co., Ltd. has proposed a 2024 Employee Stock Ownership Plan (ESOP) aimed at aligning the interests of employees and shareholders, enhancing corporate governance, and promoting long-term sustainable development [3][12][16]. Group 1: Plan Overview - The ESOP is designed to comply with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [3][12]. - The plan will be managed by a dedicated committee, which will represent the interests of the participants and ensure compliance with legal requirements [9][25]. - The total amount to be raised through the plan is capped at RMB 37.7868 million, with each unit priced at RMB 1.00 [4][14]. Group 2: Participants and Structure - The plan will involve a maximum of 35 employees, including directors (excluding independent directors), supervisors, senior management, and core business personnel [4][13]. - The stock purchase price is set at RMB 26.15 per share, which is based on a fair valuation considering the company's performance and market conditions [15][16]. - The total shares allocated under the plan will not exceed 1.445 million shares, representing approximately 0.35% of the company's total share capital [5][18]. Group 3: Lock-up and Vesting - The plan has a duration of 48 months, with shares unlocking in two phases: 50% after 12 months and the remaining 50% after 24 months [6][21]. - The unlocking of shares is contingent upon the company's performance meeting specific revenue growth targets, which are set against the 2023 revenue of RMB 2.709 billion [22][23]. Group 4: Financial Management and Compliance - The company will not provide any financial assistance to participants, ensuring that all funding comes from employees' legal salaries and self-raised funds [4][14]. - The management committee will oversee the daily operations of the ESOP, ensuring that all actions comply with the established guidelines and protect the rights of the participants [25][30]. - The plan includes provisions for adjusting the stock purchase price in the event of corporate actions such as stock splits or dividends [16][17].

Core Points - Shenzhen BGI Tech Co., Ltd. held the first meeting of the 2024 Employee Stock Ownership Plan on August 21, 2025, with 25 attendees representing 34,797,962 shares, accounting for 94.40% of the total shares in the plan [1][2] - The meeting approved the revised draft of the 2024 Employee Stock Ownership Plan and its summary to ensure the smooth implementation of the plan and protect the rights of shareholders [1] - The meeting also approved the revised management measures for the 2024 Employee Stock Ownership Plan, aligning with relevant regulations and actual circumstances [2] Summary by Sections Employee Stock Ownership Plan - The 2024 Employee Stock Ownership Plan was discussed and approved, with a focus on performance assessment indicators at the company level to ensure its effectiveness [1] - The plan's total shares represented by attendees was 34,797,962, with unanimous approval (100%) from those present [2] Management Measures - The management measures for the 2024 Employee Stock Ownership Plan were revised to align with the updated draft and ensure smooth implementation [2] - The voting results showed full support with no opposition or abstentions [2]

Core Viewpoint - Shenzhen BGI Genomics Co., Ltd. plans to revise its 2024 restricted stock incentive plan and employee stock ownership plan to enhance employee motivation and align with the company's strategic goals in the context of the evolving market environment [10][11]. Summary by Sections Incentive Plan Overview - The incentive plan involves granting restricted stocks to key personnel, including directors, senior management, and core technical staff, to align their interests with the company's long-term performance [1][4]. Necessary Procedures - The company has followed necessary procedures, including board meetings and shareholder approvals, to implement the incentive plan and employee stock ownership plan [5][6][7]. Revision Reasons - The revision is driven by the need to adapt to changes in the external environment and to focus on increasing market share in the gene sequencing equipment sector, which is critical for long-term revenue growth [10][11]. Revised Performance Metrics - The revised performance metrics will include non-related party gene sequencing instrument sales as a key performance indicator, aiming to enhance the company's competitive position and employee engagement [11][12]. Conclusion - The independent financial advisor confirms that the revisions to the incentive plan and employee stock ownership plan have met the necessary review and disclosure obligations and are pending shareholder approval for implementation [14][15].

Core Viewpoint - The company has revised its 2024 Restricted Stock Incentive Plan and Employee Stock Ownership Plan to enhance employee motivation and align with its strategic goals, particularly focusing on increasing market share in the gene sequencing industry [1][11]. Group 1: Decision Process and Disclosure - The company has completed the necessary decision-making procedures and disclosures for the 2024 Restricted Stock Incentive Plan and Employee Stock Ownership Plan, which require approval from the shareholders' meeting to be implemented [2][12]. - The supervisory board has verified the related matters of the incentive plan and provided relevant opinions [4][11]. Group 2: Reasons for Revision - The revision aims to adapt to changes in the external environment and the company's actual situation, adding performance assessment indicators related to the sales volume of gene sequencers excluding related parties [6][10]. - The company believes that capturing market share in gene sequencer sales is crucial for driving subsequent reagent sales and revenue growth [6][10]. Group 3: Revised Content - The revised performance assessment indicators now include the sales volume of gene sequencers excluding related parties, with specific targets set for the first and second vesting periods [7][9]. - The performance completion rates and corresponding vesting ratios have been adjusted to reflect the new assessment criteria [8][9]. Group 4: Impact of Revisions - The revisions are expected to effectively motivate employees and support the company's strategic and operational goals without adversely affecting its financial status or operational performance [11][12]. - The adjustments are designed to enhance the company's competitiveness and market coverage, particularly in the context of increasing pressure from macroeconomic factors and competition [10][11].

Core Viewpoint - Shenzhen BGI Intelligent Manufacturing Technology Co., Ltd. (referred to as "BGI Intelligent Manufacturing" or "the Company") has established a revised employee stock ownership plan for 2024, aiming to enhance employee motivation and align their interests with those of the company and its shareholders [1][29]. Summary by Sections Chapter 1: General Provisions - The employee stock ownership plan is formulated in accordance with relevant laws and regulations, including the Company Law and Securities Law of the People's Republic of China [1]. Chapter 2: Formulation of the Stock Ownership Plan - The plan adheres to principles of legality, voluntary participation, and risk-bearing by participants [2][3]. - Eligible participants include up to 35 employees, specifically directors (excluding independent directors), supervisors, senior management, and core business personnel [2][3]. - The total funding for the plan is capped at RMB 37.7868 million, with a subscription unit priced at RMB 1.00 per share, and a maximum of 37.7868 million shares available for subscription [3][4]. Chapter 5: Asset Composition and Rights Distribution of the Stock Ownership Plan - The assets of the plan include the company's stock, cash deposits, and other investments [23]. - Upon the expiration of the lock-up period, the management committee will determine the method of disposing of the stock and distributing assets to participants [24]. Chapter 6: Changes, Termination, and Rights Disposal of the Stock Ownership Plan - The plan may be terminated if there is a change in the actual controller of the company or in the event of a merger or division [25]. - Any changes to the plan during its duration require approval from the majority of participants [25]. Chapter 8: Lock-up Period and Performance Assessment - The lock-up period for the stock is set at 12 months and 24 months, with 50% of the shares unlocking at each interval [9]. - Performance assessments will be based on the company's revenue growth and sales of gene sequencers, with specific targets set for each assessment period [11][12]. Chapter 9: Management of the Stock Ownership Plan - The management committee, elected by the participants, will oversee the plan's implementation and ensure compliance with relevant regulations [16][18]. - The company board is authorized to handle all matters related to the stock ownership plan, including its establishment, changes, and termination [21]. Chapter 10: Rights and Obligations of the Company and Participants - Participants have the right to vote and receive dividends, while they are obligated to comply with the plan's regulations [22]. - The company is responsible for supporting the plan and ensuring its compliance with laws and regulations [22]. Chapter 11: Legal Compliance and Interpretation - The plan will be interpreted by the company's board and must be approved by the shareholders' meeting before implementation [28]. - In case of conflicts with new regulations, the latest legal provisions will prevail [28].